Maravai LifeSciences Holdings, Inc. financials

MRVI CIK 0001823239

Source: EDGAR filings · Built 2026-06-04T02:28:16Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Free Cash Flow -71.51M -22.83M 60.34M 518.89M 353.72M 126.58M
EBITDA -163.76M -187.23M 8.61M 606.05M 579.40M 145.81M
Working Capital 251.33M 372.18M 612.44M 737.76M 646.26M 200.82M
Net Debt 147.82M 54.29M 36.01M -46.88M 23.95M 298.43M
Gross Margin 18.30% 41.79% 48.52% 80.87% 82.41% 71.96%
Operating Margin -115.89% -90.91% -10.95% 65.03% 69.40% 42.20%
Net Margin -70.41% -55.89% -41.19% 24.94% 22.78% 31.32%
Return on Equity (ROE) -61.58% -44.53% -28.56% 40.39% 57.70% 100.52%
Return on Assets (ROA) -16.97% -14.37% -8.00% 9.65% 9.49% 7.00%
Current Ratio 6.60× 7.53× 8.00× 7.70× 7.89× 2.54×
Debt-to-Equity 1.72× 1.16× 1.47× 1.07× 1.82× 6.04×
Effective Tax Rate 1.79% 0.71% 122.40% 11.03% 11.59% 3.53%
Cash Conversion Ratio 0.44× -0.05× -1.06× 2.43× 2.02× 1.71×
Accruals Ratio -0.10× -0.15× -0.16× -0.14× -0.10× -0.05×
SBC % of Revenue 16.25% 19.07% 11.97% 2.11% 1.31% 8.67%
CapEx Coverage -4.13× 0.25× 1.92× 31.36× 24.82× 5.94×
Free Cash Flow Per Share $-0.50 $-0.17 $0.46 $2.03 $1.37 $4.38

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
P/E Trailing (Diluted) 8.57× 26.86× 11.89×
P/FCF 14.32× 7.04× 30.54× 6.41×
FCF Yield 6.98% 14.20% 3.27% 15.61%
EV / EBITDA 104.59× 5.95× 18.68× 7.61×
P/S 2.53× 2.90× 2.99× 4.14× 13.52× 2.85×
P/B 2.21× 2.31× 2.07× 6.70× 34.24× 9.16×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Revenue from Contract with Customer, Excluding Assessed Tax 185.74M 259.19M 288.94M 883.00M 799.24M 284.10M
Cost of Revenue 151.75M 150.88M 148.74M 168.96M 140.56M 79.65M
Gross Profit 33.99M 108.31M 140.20M
Research and Development Expense 17.40M 19.22M 17.28M 18.37M 15.22M 9.30M
Selling, General and Administrative Expense 145.12M 161.77M 151.39M 129.26M 100.06M 94.25M
Operating Income (Loss) -215.27M -235.62M -31.65M 574.22M 554.64M 119.90M
Income Tax Expense (Benefit) -4.21M -1.86M 756.11M 60.81M 61.52M 2.88M
Net Income (Loss) Attributable to Parent -130.77M -144.85M -119.03M 220.21M 182.04M 88.97M
Earnings Per Share, Basic $-0.90 $-1.05 $-0.90 $1.67 $1.59 $7.43
Weighted Average Number of Shares Outstanding, Basic 144.36M 137.91M 131.92M 131.54M 114.79M 10.35M
Earnings Per Share, Diluted $-0.90 $-1.05 $-0.90 $1.67 $1.56 $2.36
Weighted Average Number of Shares Outstanding, Diluted 144.36M 137.91M 131.92M 255.32M 257.80M 28.91M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Cash and Cash Equivalents, at Carrying Value 216.89M 322.40M 574.96M 632.14M
Assets, Current 296.25M 429.15M 699.91M 847.90M 740.04M 331.60M
Assets 770.58M 1.01B 1.49B 2.28B 1.92B 1.27B
Long-term Debt 291.77M 295.93M 524.15M 527.44M 530.59M 534.61M
Liabilities, Current 44.92M 56.97M 87.47M 110.14M 93.78M 130.78M
Long-term Debt, Excluding Current Maturities 286.33M 290.49M 518.71M 522.00M 524.59M 528.61M
Liabilities 397.87M 431.04M 697.57M 1.38B 1.37B 1.12B
Stockholders' Equity Attributable to Parent 212.38M 325.29M 416.75M 545.22M 315.50M 88.51M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Net Cash Provided by (Used in) Operating Activities -57.57M 7.46M 126.22M 535.98M 368.57M 152.19M
Payments to Acquire Property, Plant, and Equipment 13.15M 29.66M 65.55M 17.09M 14.85M 25.41M
Net Cash Provided by (Used in) Investing Activities -31.41M -24.32M -122.31M -267.61M 105.66M 6.07M
Payments for Repurchase of Common Stock 0 0 33.66M
Net Cash Provided by (Used in) Financing Activities -16.50M -235.71M -61.09M -187.50M -159.05M 53.21M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (MRVI CIK 0001823239), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

DIBS

1stdibs.com, Inc.

MWYN

MARWYNN HOLDINGS, INC.

VEL

Velocity Financial, Inc.